Today

Agents

Chat

Arena

Discover

More

App

Xeris to host XP-8121 hypothyroidism program overview webinar - XERS News | Rallies

Xeris to host XP-8121 hypothyroidism program overview webinar

XERS•2026-08-26

Focus of the session

The session focuses on its Phase 3-ready, once-weekly subcutaneous levothyroxine candidate for hypothyroidism, including Phase 3 trial plans.

Webinar scheduled for September 9

Xeris Biopharma schedules an XP-8121 program overview webinar for September 9, 2026 at 10 a.m. ET.

Related News

Future Vision II Acquisition held extraordinary shareholder meeting in Shanghai

FVN•2026-08-26

DICK'S Sporting Goods <DKS.N>: Morgan Stanley cuts target price to $180.00 from $270.00

DKS•2026-08-26

Venu director Thomas Finke acquires 30,000 common shares worth $57,600

•

2026-08-26

FTC Solar CEO Anthony Carroll acquires 24,745 shares worth $51,469.60

FTCI•2026-08-26

ZIM CFO Xavier Destriau sells 12,084 shares for $348,019.20

ZIM•2026-08-26